Loading company
Starling Oncology, Inc.
STLN · Nasdaq · ·
$6.53-1.8%Sep 29 close
- 1M
- +5.8%
- 6M
- +130.7%
- 1Y
- +87.1%
- 5Y
- -34.2%
Starling Oncology, Inc. is the 31st largest of 44 graded companies. Showing 5 of them, including STLN itself. 5 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc.GRDN | A | — | $1.5B | 4.5% | $86.8M | — |
| HCA Healthcare, Inc.HCA | A | $95.7B | $76.4B | 8.9% | $7.9B | 14.86 |
| Tenet Healthcare Corp.THC | A+ | $20.8B | $21.8B | 14.6% | $3B | 9.94 |
| Encompass Health CorporationEHC | B+ | $12.2B | $6.2B | 10.0% | $413.4M | 20.13 |
| Starling Oncology, Inc.STLN | B | $665.5M | $587.2M | -6.2% | -$3.3M | — |
39 more medical care facilities companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Starling Oncology, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
STLN · Nasdaq · ·
$6.53-1.8%Sep 29 close